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Docking studiesAbstract We report herein, two synthetic approaches to three types of nitrogen-containing bispho-
sphonates (N-BPs) in moderate to high yields (58–88%). Ester cleavage of selected bisphosphonates
was undertaken to obtain their N-BP-acid analogs. Based on the reported bisphosphonate proper-
ties and the prospective biological prediction using computer-assisted molecular modeling
(CAMM), new compounds were evaluated in a mouse model of antigen-induced arthritis (AIA)
and the delayed-type hypersensitivity granuloma reaction (DTH-GRA) for chronic inflammation.
Pharmacological results showed that N-BP-acids are more favorable for antiarthritis activity than
N-BP-esters. On the other hand, the majority of N-BPs revealed good antiinflammatory potency
compared to their acid analogs. The results also showed that the presence of a free thiol group
in a molecule enhances the anti-inflammatory activity. Furthermore, bioscreening results were in
good agreement with the prediction investigation. A hypothesis of molecular modeling study,
including fitting of the synthesized compounds into 3D-pharmacophore using Discovery Studio
2.5 software and their docking into the human farnesyl pyrophosphate synthase (hFPPS, PDB
code: 2F8C protein) showed good results consistent with the observed pharmacological properties.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Bisphosphonates (BPs) are synthetic pyrophosphate mimics, which
have been developed and used for the treatment of bone diseases
(Fig. 1, Emesto et al., 2007). The pronounced selective activity of
BPs for bone tissues gives them a key advantage in clinical practice
and the mainstay of antiresorptive therapy for osteoporosisdocking
2 W.M. Abdou et al.(Balakrishna et al., 2011; Emesto et al., 2007; Fleisch, 1988, 1995). BPs
inhibit bone resorption by reducing osteoclast activity and inducing
osteoclast apoptosis (Balakrishna et al., 2011; Fleisch, 1995, 1988).
They are therefore, used for treatment post-menopausal osteoporosis
in women and reducing the associated bone fracture risk (Cheng and
Oldfield, 2004).
Nitrogen-containing bisphosphonates are known as the second
generation of BPs and are proven to be more effective. These drugs
are used in diverse therapeutic areas such as microbial (Wang et al.,
2001), parasitic (Docampo and Moreno, 2001), herbicidal
(Cromartie et al., 1999), viral (HIV) (Mckenna et al., 1999), cancer
diseases (Fleisch, 2002; Senaratne and Colston, 2002) as well as
chronic inflammation and arthritis (Francis et al., 1989; Nugent
et al., 1993; O¨sterman et al., 1997). The activity of N-BPs has
accounted to their effect on human farnesyl (hFPP)-and human ger-
anyl geranyl pyrophosphate synthase (hGGPP), which are enzymes
in the mevalonate pathway, decreasing the prenylation of essential
GTP-binding proteins (Dunford et al., 2006). Furthermore, it is well
established that N-BPs bearing free amine group (or alkylated
amine, known as the third generation of BPs) at one of the side
chains are usually preferable in clinical use because of their higher
potency (Bijvoet et al., 1995).
In human rheumatoid arthritis (RA), osteoclasts are found at
sites of tissues invasion and emerge from synovial inflammatory tis-
sues (Hannig et al., 2007; O¨sterman et al., 1997), therefore, inhibi-
tion of osteoclastogenesis is a powerful approach to prevent
arthritic bone destruction (Hannig et al., 2007). As a part of our
ongoing research program on the applications of BPs in pharmacol-
ogy (Abdou et al., 2014, 2012b,c,d; Kamel et al., 2012; Shaddy
et al., 2013), we herein, accomplished a synthesis of a variety of
b-aminobisphosphonates and their relevant bisphosphonic acids.
New compounds were examined vs RA in animal antigen-induced
arthritis (AIA) and for the chronic inflammation in animal model
of the delayed-type hypersensitivity granuloma reaction (DTH-
GRA). The optimized antiarthritis/antiinflammatory activities of
synthesized N-BPs and N-BP-acids are also based on the prospective
predicted potency, using the computer-assisted molecular modeling
(CAMM) (Da Silva et al., 2010; Lagunin et al., 2003). Later, a
hypothesis of molecular modeling study, including fitting of the syn-
thesized compounds into 3D-pharmacophore using Discovery Studio
2.5 software (Girgis et al., 2011; Shahin et al., 2014) and their dock-
ing into the human farnesyl pyrophosphate synthase (hFPPS, PDB
code: 2F8C protein) showed good results consistent with the
observed pharmacological properties.
2. Material and methods
2.1. General data
Melting points were determined with open capillary tube on an
Electrothermal (variable heater) melting point apparatus and
were not corrected. IR spectra were recorded on a JASCO
FT-IR 6100 using KBr disk (JASCO, Japan). NMR spectra
were measured with a JEOL E.C.A-500 MHz (13C:
125.7 MHz, 1H: 500 MHz, 31P: 202.4 MHz) spectrometer
(JEOL, Japan). 31P NMR spectra were recorded with H3PO4
(85%) as external reference. 1H and 13C NMR spectra were
recorded with trimethylsilane as internal standard in CDCl3.
Chemical shifts (d) are given in ppm. The mass spectra were
performed at 70 eV on an MS-50 Kratos (A.E.I.) spectrometer
provided with a data system spectrometer (Kratos, UK). Ele-
mental analyses were carried out at the Microanalysis Labora-
tory, Cairo University, Cairo, Egypt, using elementary
Analysen-systeme GmbH-vario EL III Element Analyzer,
Germany. The appropriate precautions in handlingPlease cite this article in press as: Abdou, W.M. et al., Developing eﬃcient protoc
studies of nitrogen-containing bisphosphonate derivatives. Arabian Journal of Chemmoisture-sensitive compounds were observed. The purity of
all new samples was verified by microchemical analysis
(C/H/N/S) and spectroscopy. Solvents were dried by standard
techniques. Thin-layer chromatography (TLC): Merck 0.2 mm
silica gel 60 F254 analytic aluminum plates. All international
principles and local regulations concerning the care and the
use of laboratory animals were considered during the pharma-
cological screening. The azide 2 was prepared according to the
reported method (Pokhodylo et al., 2010).
2.2. Preparation of tetraethyl (3-amino-4,5,6,7-tetrahydro-2H
[1]benzothieno[2,3-b]pyrrole-2,2-diyl)bisphosphonate (4)
A solution of tetraethyl methylenebisphosphonate (0.9 g,
3.2 mmol) of (1) in absolute ethanol (10 mL) containing
sodium (80 mg, 3.5 mmol) was stirred at 0 C for 0.5 h. A
solution of 2-azido-4,5,6,7-tetrahydrobenzo[b]thiophene-3-
carbonitrile (2) (0.6 g, 3 mmol) in EtOH (10 mL) was then
added in one portion, and the reaction mixture was stirred
under reflux for 6 h (TLC). The product mixture was cooled,
poured into iced water, and acidified with conc HCl, followed
by extraction with AcOEt, dried, and the volatile materials
were removed under reduced pressure until dryness. Crystal-
lization of the resulting residue from MeCN afforded the bis-
phosphonate 4 as strew yellow crystals. Yield: 1.2 g (87.6%);
mp 162–164 C; tmax/cm1 3441–3333 (NH2), 1254 (P‚O,
free), 1234 (P‚O, H-bonded), 1075, 1029 (2PAOAC); dH
(500 MHz, CDCl3) 1.24, 1.35 (2dt,
3JHH = 6.7,
4JPH = 4.4
Hz, 12H, 4H3CH2COP), 1.91, 2.45 (2 m, 8H, 4H2C-hexyl),
4.04–4.27 (m, 8H, 4H2COP), 6.36, 8.73 (2br, 2H, H2N, D2O,
exchanged); dC (125.7 MHz, CDCl3) 167.8 (t,
3JPC = 7.4 Hz,
C‚N), 141.6, 134.6 (C‚C-hexyl), 120.6 (t, 2JPC = 33.6 Hz,
CANH2), 102.7 (t,
3JPC = 7.1 Hz, C‚CANH2), 77.4 (t,
1JPC = 179.4 Hz, C-P2), 62.1 (d,
2JPC = 13.7 Hz, 4CH2OP),
26.4, 25.1, 23.6, 22.3 (CH2-hexyl), 16.5 (d,
3JPC = 7.5 Hz,
4CH3H2COP); dP (202.4 MHz, CDCl3) 21.5, 24.2 (2d,
2JPP = 24.2 Hz, C-P2); m/z (%) 462 [M
+2, 65%], 188 [100,
M+276 (2H + 2[P(O)(OEt)2])]. Anal. calcd. for C18H30N2-
O6P2S (464.45): C, 46.55; H, 6.51; N, 6.03; S, 6.90. Found:
C, 46.62; H, 6.45; N, 5.96; S, 6.84.
2.3. Preparation of ethyl 4-azido-5-cyano-1-phenyl-1H-
pyrazole-3-carboxylate (6)
A solution of NaNO2 (2.76 g, 40 mmol) in water (20 mL) was
added to a solution of ethyl 4-amino-5-cyano-1-phenyl-1H-
pyrazole-3-carboxylate (7.68 g, 30 mmol) in 10% aqueous
HCl (120 mL) at 0–5 C. The reaction mixture was stirred at
this temperature for 30 min, any resinous sediment that has
formed should be filtered, followed by adding a solution of
NaN3 (3.25 g, 50 mmol) in water (50 mL). The mixture was
further stirred for 1 h and the precipitate was filtered off,
washed with water, and dried. The resulting residue was crys-
tallized from cyclohexane to give 6 as pale yellow crystals.
Yield: 6.5 g (76.5%); mp 158–160 C; tmax/cm1 2219 (CN),
2152 (N3), 1704 (C‚O); dH (500 MHz, CDCl3) 1.23 (t,
3JHH = 6.5 Hz, 3H, H3CH2CO), 4.35 (q,
3JHH = 6.5 Hz, 2H,
H2CO), 7.55–7.62 (m, 5H, H-Ph); dC (125.7 MHz, CDCl3)
160.2 (C‚O), 142.1, 136.3, 128.1, 126.4, 125.5, 111.5, 101.4
(C-pyrazole, C-Ph), 122.1 (CN), 61.3 (CH2O), 13.6 (CH3H2-
CO); m/z (%) 282 [M+, 74%], 254 [100, M+28]. Anal. calcd.ols for synthesis, antiosteoarthritic, antiinﬂammatory assessments and docking
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C, 55.39; H, 3.43; N, 29.64.
2.4. Preparation of ethyl 6-amino-5,5-bis(diethoxyphosphoryl)-
1-phenyl-1,5-dihydropyrrolo-[3,2-c]pyrazole-3-carboxylate (7)
Following the previous procedure described for the synthesis
of compound 4 and using the same amounts, the azide 6
(0.8 g, 3 mmol) reacted with 1 (0.9 g, 3.2 mmol) in EtONa
(80 mg, 3.5 mmol) solution at r.t. for 6 h. The product mixture
was cooled, poured into iced water, and acidified with conc
HCl, followed by extraction with AcOEt, dried, and the vola-
tile materials were removed under reduced pressure until dry-
ness. Crystallization of the resulting residue from CHCl3
afforded the bisphosphonate 7 as pale yellow crystals. Yield:
1.4 g (84.8%); mp 186–188 C; tmax/cm1 3429–3334 (NH2),
1259 (P‚O, free), 1229 (P‚O, H-bonded), 1130, 1072
(2PAOAC); dH (500 MHz, CDCl3) 0.97 (t,
3JHH = 6.5 Hz,
3H, H3CH2CO), 1.26, 1.38 (2dt,
3JHH = 5.3,
4JPH = 4.2 Hz,
12H, 4H3CCH2OP), 4.18 (q,
3JHH = 6.5 Hz, 2H, H2CO),
4.32–4.45 (m, 8H, 4H2COP), 6.43, 8.94 (2br, 2H, H2N, D2O,
exchanged), 7.52–7.69 (m, 5H, H-Ph); dC (125.7 MHz, CDCl3)
158.7 (t, 3JPC = 7.2 Hz, C‚N), 157.6 (C‚O), 148.2, 141.3,
129.5, 124.5, 115.2 (C-Ph, C-pyrazole), 116.2 (t, 3JPC = 9.5
Hz, C‚CANH2), 106.3 (t,
2JPC = 34.5 Hz, CANH2), 73.6
(t, 1JPC = 175.3 Hz, C-P2), 62.4 (d,
2JPC = 10.7 Hz, 4CH2OP),
61.2 (CH2O), 16.5 (d,
3JPC = 6.9 Hz, 4CH3H2COP), 14.3
(CH3CH2O); dP (202.4 MHz, CDCl3) 27.6, 28.3 (2d,
2JPP = 21.5 Hz, C-P2); m/z (%) 540 [M
+2, 65%], 221 [100,
M+321 (2H + OEt + 2[P(O)(OEt)2])]; Anal. calcd. for
C22H32N4O8P2 (542.46): C, 48.71; H, 5.95; N, 10.33. Found:
C, 48.79; H, 5.81; N, 10.27.
2.5. Preparation of nitrogen-bisphosphonates (N-BPs, 11a–d)
Step 1: to a solution of azide 6 (2.82 g, 10 mmol) in CH2Cl2
(10 mL), triphenylphosphine (PPh3) (3.27 g, 12.5 mmol) in
CH2Cl2 (10 mL) was added. The reaction mixture was stirred
at r.t. for 6 h and the volatile materials were removed under
vacuum. The precipitated material was collected (4.65 g,
90.2%), washed with ligroin to give the iminophosphorane
(A) as colorless material in 90.2% yield (Abdou et al.,
2012a). Compound A is pure enough and stable for few days
at 10 C; Step 2: to a solution of A (1.29 g, 2.5 mmol) in
THF (15 mL), methyl-, ethyl-, phenyl-, and/or cyclohex-
aneisocyanate (9a–d, 2.5 mmol) were added at r.t. After the
mixture was stirred for 8 h (TLC) at 0 to 5 C, the solvent
was distilled off in vacuum, and the residue was washed thor-
oughly with ether/petroleum ether (1:2, 20 mL) to get rid of
Ph3PO, yielding the carbodiimides 10. Compounds 10a–d
(80%) were generally used directly without further purifica-
tion; Step 3: to the in situ carbodiimides 10a–d (2 mmol),
phosphoryl carbanion 1 (0.69 g, 2.4 mmol) in EtONa solution
(64 mg Na, 2.8 mmol/20 mL EtOH) was added in one por-
tion, and the mixture was further stirred at r.t. for 8–10 h
(TLC). The product mixture was cooled-up, poured into iced
water, and acidified with conc HCl, followed by extraction
with AcOEt, dried, and the volatile materials were removed
under reduced pressure until dryness. The resulting residue
was crystallized from the proper solvent to give the bisphos-
phonates 11a–d.Please cite this article in press as: Abdou, W.M. et al., Developing eﬃcient protoco
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(methylimino)-1-phenyl-5,6-dihydro-1H-pyrazolo[4,3-b]
pyridine-3-carboxylate (11a) was obtained as pale yellow
crystals
Yield: 0.86 g (74.4%); mp 162–164 C (CH2Cl2); tmax/cm1
3435–3342 (NH2), 1702 (C‚O), 1256, 1226 (2P‚O), 1132,
1079 (2PAOAC); dH (500 MHz, CDCl3) 1.17 (t,
3JHH = 6.7
Hz, 3H, H3CH2CO), 1.24, 1.28 (2dt,
3JHH = 6.8,
4JPH = 4.8
Hz, 12H, 4H3CH2COP), 3.3 (s, 3H, H3CN), 3.78 (q,
3JHH = 6.7 Hz, 2H, H2CO), 4.21–4.25 (m, 8H, 4H2COP),
6.31, 8.72 (2br, 2H, H2N, D2O exchanged), 7.42–7.63 (m,
5H, H-Ph); dC (125.7 MHz, CDCl3) 178.3 (t,
2JPC = 25.2 Hz,
C‚NMe), 162.6 (C‚O), 158.2, 147.5, 145.9, 129.4, 128.5,
123.7 (C-Ph, C-pyrazole), 118.8 (t, 2JPC = 28.4 Hz, CANH2),
112.4 (t, 3JPC = 8.7 Hz, C‚CANH2), 61.7 (d,
2JPC = 12.7 -
Hz, 4CH2OP), 60.2 (CH2O), 47.8 (t,
1JPC = 168.7 Hz, C-P2),
41.5 (CH3N), 16.4 (d,
3JPC = 6.8 Hz, 4CH3CH2OP), 14.5
(CH3CH2O); dP (202.4 MHz, CDCl3) 24.4, 25.6 (2d,
2JPP = 22.6 Hz, C-P2); m/z (%) 581 [M
+2, 53%], 307 [100,
M+276 (2H + 2[P(O)-(OEt)2])]. Anal. calcd. for C24H35N5-
O8P2 (583.51): C, 49.40; H, 6.05; N, 12.00. Found: C, 49.31;
H, 5.93; N, 11.93.
2.5.2. Ethyl 7-amino-6,6-bis(diethoxyphosphoryl)-5-
(ethylimino)-1-phenyl-5,6-dihydro-1H-pyrazolo[4,3-b]
pyridine-3-carboxylate (11b) was obtained as yellow crystals
Yield: 0.74 g (62.2%); mp 155–157 C (MeCN); tmax/cm1
3440–3346 (NH2), 1706 (C‚O), 1258, 1229 (2P‚O), 1136,
1076 (2PAOAC); dH (500 MHz, CDCl3): 1.11 (t,
3JHH = 6.3
Hz, 3H, H3CH2CN), 1.23 (t,
3JHH = 6.4 Hz, 3H, H3CH2CO),
1.28, 1.31 (2dt, 3JHH = 6.2,
4JPH = 5.1 Hz, 12H, 4H3CCH2-
OP), 3.51 (q, 3JHH = 6.3 Hz, 2H, H2CN), 3.75 (q,
3JHH = 6.4 Hz, 2H, H2CO), 4.11–4.26 (m, 8H, 4H2COP),
6.35, 8.69 (2br, 2H, H2N, D2O, exchanged), 7.45–7.61 (m,
5H, H-Ph); dC (125.7 MHz, CDCl3) 176.7 (t,
2JPC = 28.4 Hz,
C‚NEt), 163.6 (C‚O), 158.6, 146.9, 144.2, 129.5, 128.2,
123.5 (C-pyrazole, C-Ph), 117.5 (t, 2JPC = 27.8 Hz, CANH2),
113.5 (t, 3JPC = 8.2 Hz, C‚CANH2), 62.5 (d,
2JPC = 12.6
Hz, 4CH2OP), 61.8 (CH2O), 55.6 (CH2N), 45.6 (t,
1JPC = 167.3 Hz, C-P2), 16.3 (d,
3JPC = 7.3 Hz, 4CH3CH2-
OP), 15.6 (CH3CH2O), 14.8 (CH3CH2N); dP (202.4 MHz,
CDCl3) 26.1, 27.5 (2d,
2JPP = 23.8 Hz, C-P2); m/z (%) 595
[M+2, 63%], 321 [100, M+276 (2H + 2[P(O)(OEt)2])];
Anal. calcd. for C25H37N5O8P2 (597.54): C, 50.25; H, 6.24;
N, 11.72. Found: C, 50.38; H, 6.14; N, 11.64.
2.5.3. Ethyl 7-amino-6,6-bis(diethoxyphosphoryl)-1-phenyl-5-
(phenylimino)-5,6-dihydro-1H-pyrazolo[4,3-b]pyridine-3-
carboxylate (11c) was obtained as yellow crystals
Yield: 0.86 g (66.7%); mp 176–178 C (EtOH); tmax/cm1
3435–3343 (NH2), 1712 (C‚O), 1254, 1232 (2P‚O), 1132,
1078 (2PAOAC); dH (500 MHz, CDCl3) 1.21 (t,
3JHH = 6.8
Hz, 3H, H3CCH2O), 1.25, 1.34 (2dt,
3JHH = 7.3,
4JPH = 4.8
Hz, 12H, 4H3CCH2OP), 4.12 (q,
3JHH= 6.8 Hz, 2H, H2CO),
4.16–4.37 (m, 8H, 4H2COP), 6.33, 8.61 (2br, 2H, H2N, D2O
exchanged), 7.36–7.63 (m, 10H, H-Ph); dC (125.7 MHz, CDCl3)
177.4 (t, 2JPC = 27.3 Hz, C‚NPh), 162.4 (C‚O), 158.9, 156.3,
147.5 145.3, 129.6, 128.7, 126.2, 123.6, 123.1 (C-pyrazole, C-
Ph), 117.5 (t, 2JPC = 29.4 Hz, CANH2), 112.7 (t,
3JPC = 9.2 -
Hz, C‚CANH2), 61.7 (d,
2JPC = 11.6 Hz, 4CH2OP),
61.3 (CH2O), 46.5 (t,
1JPC = 181.3 Hz, C-P2), 16.4ls for synthesis, antiosteoarthritic, antiinﬂammatory assessments and docking
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(202.4 MHz, CDCl3) 25.7, 27.1 (2d,
2JPP = 24.1 Hz, C-P2)
ppm; m/z (%) 643 [M+2, 63%], 369 [100, M+276
(2H + 2[P(O)(OEt)2])]; Anal. calcd. for C29H37N5O8P2
(645.58): C, 53.95; H, 5.78; N, 10.85. Found: C, 54.04;
H, 5.69; N, 10.71.
2.5.4. (Ethyl 7-amino-5-(cyclohexylimino)-6,6-bis
(diethoxyphosphoryl)-1-phenyl-5,6-dihydro-1H-pyrazolo[4,3-
b]pyridine-3-carboxylate (11d) was obtained as yellow crystals
Yield: 0.94 g (72.3%); mp 165–166 C (diethyl ether);
tmax/cm
1 3439–3333 (NH2), 1705 (C‚O), 1259, 1230
(2P‚O), 1130, 1072 (2PAOAC); dH (500 MHz, CDCl3)
0.9, 1.19 (2 m, 8H, 4H2C), 1.47 (t,
3JHH = 6.9 Hz, 3H, H3-
CH2CO), 1.61, 1.73 (2dt,
3JHH = 6.2,
4JPH = 4.7 Hz, 12H,
4H3CCH2OP), 1.82 (m, 2H, H2C), 2.6 (m, 1H, HC), 4.32
(q, 3JHH = 6.9 Hz, 2H, H2CO), 4.41–4.56 (m, 8H,
4H2COP), 6.34, 8.74 (2br, 2H, H2N, D2O exchanged),
7.67–7.89 (m, 5H, H-Ph); dC (125.7 MHz, CDCl3) 166.5
(t, 2JPC = 29.5 Hz, C‚NC6H11), 162.7 (C‚O), 158.6,
147.8, 145.7, 129.4, 128.3, 123.6 (C-pyrazole, C-Ph), 118.2
(t, 2JPC = 27.8 Hz, CANH2), 112.4 (t,
3JPC = 8.9 Hz,
C‚CANH2), 61.9 (d,
2JPC = 11.2 Hz, 4CH2OP), 60.8
(CH2O), 56.3 (CH-cyclohexane), 45.6 (t,
1JPC = 178.5 Hz,
C-P2), 29.4, 25.6, 23.2 (CH2-cyclohexane), 16.5
(d, 3JPC = 8.6 Hz, 4CH3CH2OP), 14.6 (6CH3CH2O); dP
(202.7 MHz, CDCl3) 26.2, 27.6 (2d,
2JPP = 36 Hz, C-P2);
m/z (%) 649 [M+2, 64%], 375 [100, M+276 (2H + 2[P
(O)(OEt)2])]. Anal. calcd. for C29H43N5O8P2 (651.63): C,
53.45; H, 6.65; N, 10.75. Found: C, 53.31; H, 6.56; N, 10.62.
2.6. Preparation of nitrogen-bisphosphonates 16a–d
A mixture of 2-aminobenzenethiol (13) (1.25 g, 10 mmol) and
aldehyde: 4-(dimethylamino)-, 4-hydroxy-, 2-hydroxy-, or 4-
methoxy-benzaldehyde 14a–d (10 mmol) in EtOH (20 mL)
containing AcOH (1 mL) was stirred under reflux for 3 h
(TLC). The resulting Schiff-bases 15a–d were precipitated
and allowed to react in situ with 1. Phosphoryl carbanion 1
(1.2 g, 4.2 mmol) in DMF (20 mL) containing LiH (0.1 g,
12.6 mmol) was added under stirring to the substrates 15a–d
(3.5 mmol). The suspension was stirred at r.t. for further
30 min and then heated under reflux for the appropriate time
18 h (TLC). The product mixture was cooled-up, poured into
iced water, and acidified with conc HCl, followed by extraction
with AcOEt, dried, and the volatile materials were removed
under reduced pressure until dryness. The resulting residue
was crystallized from the proper solvent to give the bisphos-
phonates 16a–d.
2.6.1. Tetraethyl {2-(4-(dimethylamino)phenyl)-2-[(2-
mercaptophenyl)amino]ethane-1,1-diyl}bisphosphonate (16a)
was obtained as buff crystals
Yield: 1.3 g (68.3%); mp 170–172 C (MeCN); tmax/cm1
3429–3357 (NH), 2565 (SH, free), 1254, 1228 (2P‚O), 1090,
1028 (2PAOAC); dH (500 MHz, CDCl3) 1.14, 1.18 (2dt,
3JHH = 6.3,
4JPH = 4.4 Hz, 12H, 4H3CCH2OP), 2.88 (br,
1H, HS, D2O exchanged), 2.94 (s, 6H, Me2N), 3.84 (td,
3JHH = 9.8,
2JPH = 17.7 Hz, 1H, HC-P2), 4.13–4.26 (m, 8H,
4H2COP), 4.45 (td,
3JHH = 9.8,
3JPH = 6.8 Hz, 1H, HC-Ar),
6.64–7.42 (m, 8H, H-Ar), 9.12 (br, 1H, HN, D2O exchanged);Please cite this article in press as: Abdou, W.M. et al., Developing eﬃcient protoc
studies of nitrogen-containing bisphosphonate derivatives. Arabian Journal of ChemdC (125.7 MHz, CDCl3) 149.8, 148.5, 131.4, 129.3, 125.6,
122.5, 115.7, 114.2 (C-Ar), 139.3 (t, 3JPC = 8.9 Hz, C-Ar),
64.5 (t, 2JPC = 26.7 Hz, CHANH), 60.5 (d,
2JPC = 12.8 Hz,
4CH2OP), 44.7 (t,
1JPC = 182.4 Hz, C-P2), 40.1 (Me2C), 15.7
(d, 3JPC = 8.4 Hz, 4CH3CH2OP); dP (202.4 MHz, CDCl3)
24.3, 25.6 (2d, 2JPP = 23.9 Hz, C-P2); m/z (%) 542 [M
+2,
65%], 254 [100, M+290 (2H + CH2[P(O)(OEt)2]2)]. Anal.
calcd. for C24H38N2O6P2S (544.58): C, 52.93; H, 7.03; N,
5.14; S, 5.89. Found: C, 53.01; H, 6.96; N, 5.06; S, 6.02.
2.6.2. Tetraethyl {2-(4-hydroxyphenyl)-2-[(2-mercaptophenyl)
amino]ethane-1,1-diyl}bisphosphonate (16b) was obtained as
buff crystals
Yield: 1.12 g (62.2%); mp 144–146 C (CH2Cl2); tmax/cm1
3421–3373 (OH & NH), 2555 (SH), 1260, 1242 (2P‚O),
1087, 1030 (2PAOAC); dH (500 MHz, CDCl3) 1.16, 1.19
(2dt, 3JHH = 5.6,
4JPH = 4.6 Hz, 12H, 4H3CCH2OP), 2.91
(br, 1H, HS, D2O exchanged), 3.87 (td,
3JHH = 10.1,
2JPH = 18.4 Hz, 1H, HC-P2), 4.11–4.31 (m, 8H, 4H2COP),
4.51 (td, 3JHH = 10.1,
3JPH = 7.1 Hz, 1H, HC-Ar), 6.62–
7.35 (m, 8H, H-Ar), 9.34 (br, 1H, HN, D2O exchanged),
10.43 (br, 1H, HO, D2O exchanged); dC (125.7 MHz, CDCl3)
157.5, 149.8, 130.3, 129.3, 125.6, 122.7, 119.5, 115.6 (C-Ar),
141.6 (t, 3JPC = 9.1 Hz, C-Ar), 64.7 (t,
2JPC = 27.4 Hz,
CHANH), 60.4 (d, 2JPC = 11.7 Hz, 4CH2OP), 44.5 (t,
1JPC = 185.4 Hz, C-P2), 15.4 (d,
3JPC = 7.6 Hz, 4CH3CH2-
OP); dP (202.4 MHz, CDCl3) 23.6, 25.8 (2d,
2JPP = 23.6 Hz,
C-P2); m/z (%) 515 [M
+2, 57%], 227 [100, M+290 (2H
+ CH2[P(O)(OEt)2]2)]. Anal. calcd. for C22H33NO7P2S
(517.51): C, 51.06; H, 6.43; N, 2.71; S, 6.20. Found: C,
50.99; H, 6.37; N, 2.61; S, 6.31.
2.6.3. Tetraethyl {2-(2-hydroxyphenyl)-2-[(2-mercaptophenyl)
amino]ethane-1,1-diyl}bis-phosphonate (16c) was obtained as
buff crystals
Yield: 1.0 g (58.2%); mp 140–141 C (cyclohexane); tmax/cm1
3427–3393 (OH & NH), 2543 (SH), 1262, 1228 (2P‚O), 1085,
1033 (2PAOAC); dH (500 MHz, CDCl3) 1.14, 1.28 (2dt,
3JHH = 5.4,
4JPH = 4.6 Hz, 12H, 4H3CCH2OP), 2.95 (br,
1H, HS, D2O exchanged), 3.85 (td,
3JHH = 10.5,
2JPH = 16.8
Hz, 1H, HC-P2), 4.13–4.29 (m, 8H, 4H2COP), 4.46 (td,
3JHH = 10.5,
3JPH = 6.8 Hz, 1H, HC-Ar), 6.45–7.54 (m, 8H,
H-Ar), 9.36 (br, 1H, HN, D2O exchanged), 10.47 (br, 1H,
HO, D2O exchanged); dC (125.7 MHz, CDCl3) 161.3, 151.4,
131.3, 129.8, 125.6, 123.1, 122.4, 115.7 (C-Ar), 135.7 (t,
3JPC = 9.4 Hz, C-Ar), 60.6 (d,
2JPC = 12.5 Hz, 4CH2OP),
57.4 (t, 2JPC = 26.3 Hz, CHANH), 45.3 (t,
1JPC = 179.5 Hz,
C-P2), 15.1 (d,
3JPC = 7.4 Hz, 4CH3CH2OP); dP (202.4 MHz,
CDCl3) 23.8, 25.6 (2d,
2JPP = 23.5 Hz, C-P2); m/z (%) 515
[M+2, 62%], 227 [100, M+290 (2H + CH2[P(O)
(OEt)2]2)]. Anal. calcd. for C22H33NO7P2S (517.51): C, 51.06;
H, 6.43; N, 2.71; S, 6.20. Found: C, 50.98; H, 6.38; N, 2.65;
S, 6.29.
2.6.4. Tetraethyl 2-(2-mercaptophenylamino)-2-(4-
methoxyphenyl)ethane-1,1-diyl-bisphosphonate (16d) was
obtained as buff crystals
Yield: 1.2 g (64.6%); mp 155–157 C (CH2Cl2); tmax/cm1
3433–3365 (NH), 2552 (SH), 1261, 1240 (2P‚O), 1083, 1035
(2PAOAC); dH (500 MHz, CDCl3) 1.15, 1.23 (2dt,
3JHH = 5.9,
4JPH = 4.6 Hz, 12H, 4H3CCH2OP), 3.01 (br,ols for synthesis, antiosteoarthritic, antiinﬂammatory assessments and docking
istry (2016), http://dx.doi.org/10.1016/j.arabjc.2016.02.019
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3JHH = 10.9,
2JPH = 19.4
Hz, 1H, HC-P2), 3.95 (s, 3H, H3CO), 4.12–4.29 (m, 8H,
4H2COP), 4.51 (td,
3JHH = 10.9,
3JPH = 6.5 Hz, 1H, HC-
Ar), 6.62–7.35 (m, 8H, H-Ar), 9.34 (br, 1H, HN, D2O
exchanged); dC (125.7 MHz, CDCl3) 158.3, 149.6, 130.6,
129.5, 125.4, 122.5, 118.4, 115.7 (C-Ar), 142.4 (t, 3JPC = 9.4
Hz, C-Ar), 64.5 (t, 2JPC = 29.4 Hz, CHANH), 60.7 (d,
2JPC = 11.2 Hz, 4CH2OP), 55.7 (CH3O), 44.8 (t,
1JPC = 178.4 Hz, C-P2), 15.7 (d,
3JPC = 7.3 Hz, 4CH3CH2-
OP); dP (202.4 MHz, CDCl3) 23.6, 25.7 (2d,
2JPP = 23.8 Hz,
C-P2); m/z (%): 529 [M
+2, 57%], 241 [100, M+290 (2H
+ CH2[P(O)(OEt)2]2)]. Anal. calcd. for C23H35NO7P2S
(531.54): C, 51.97; H, 6.64; N, 2.64; S, 6.03. Found: C,
51.91; H, 6.52; N, 2.58; S, 6.12.
2.7. General procedure for N-BP-acid-salts 5A, 8A, 12aA,bA,
17aA,bA
0.63 mmol of bisphosphonates 4, 7, 11a, 11b, 16a or 16b were
dissolved in CHCl3 (10 mL) and treated with trimethylsilyl bro-
mide (3.8 mmol) and was heated at 40 C for 6 h. After con-
centrating the product mixture in vacuum, the crude material
was diluted with water and stirred for 30 min. The layers were
separated, and the aqueous layer was evaporated to dryness.
The precipitate was collected and dried to give the crude acids
5, 8, 12a, 12b, 17a or 17b. The resulted acids are hygroscopic
and can be kept only under vacuum for identification pur-
poses. The acids were later stirred in a solution of aqueous
NaOH (10%/Methanol, 20 mL (1:3 v/v) for 1 h, followed by
concentration. The precipitate 5A, 8A, 12aA, 12bA, 17aA or
17bA was filtered-off and air-dried.
2.7.1. (3-Amino-4,5,6,7-tetrahydro-2H-[1]benzothieno[2,3-b]
pyrrole-2,2-diyl)bisphosphonic acid (5) was obtained as white
substance
Yield: 0.34 g (71.6%); mp > 300 C; tmax/cm1 1252, 1227
(2P‚O); dH (500 MHz, D2O) 1.93, 2.46 (2 m, 8H, 4CH2-
hexyl); dC (125.7 MHz, D2O) 167.6 (t,
3JPC = 7.3 Hz,
C‚N), 141.4, 134.8 (C‚C-hexyl), 120.1 (t, 2JPC = 33.9 Hz,
CANH2), 102.9 (t,
3JPC = 7.5 Hz, C‚CANH2), 77.1 (t,
1JPC = 178.4 Hz, C-P2), 26.1, 24.9, 23.2, 21.7 (CH2-hexyl);
dP (202.4 MHz, D2O) 18.8, 19.4 (2d,
2JPP = 16.3 Hz, C-P2);
m/z (%) 350 [M+2, 33%]. Anal. calcd. for C10H14N2O6P2S
(352.24): C, 34.10; H, 4.01; N, 7.95; S, 9.10. Found: C,
34.21; H, 3.93; N, 7.86; S, 9.19.
2.7.2. 6-Amino-3-(ethoxycarbonyl)-1-phenyl-1,5-
dihydropyrrolo[3,2-c]pyrazole-5,5-diyldiphosphonic acid (8)
was obtained as white substance
Yield: 0.32 g (65.5%); mp > 300 C; tmax/cm1 1259, 1235
(2P‚O); dH (500 MHz, D2O) 1.35 (t,
3JHH = 7.5 Hz, 3H, H3-
CCH2O), 4.45 (q,
3JHH = 7.5 Hz, 2H, H2CO), 7.51–7.67 (m,
5H, H-Ph); dC (125.7 MHz, D2O) 158.4 (t,
3JPC = 7.4 Hz,
C‚N), 156.8 (C‚O), 147.8, 140.9, 129.2, 124.2, 116.1 (C-
Ph, C-pyrazole), 117.1 (t, 3JPC = 9.3 Hz, C‚CANH2), 106.6
(t, 2JPC = 33.9 Hz, CANH2), 72.9 (t,
1JPC = 175.6 Hz, C-
P2), 61.7 (CH2O), 14.6 (CH3CH2O); dP (202.4 MHz, D2O)
19.4, 19.6 (2d, 2JPP = 20.6 Hz, C-P2); m/z (%) 428 [M
+2,
21%]. Anal. calcd. for C14H16N4O8P2 (430.25): C, 39.08; H,
3.75; N, 13.02. Found: C, 39.17; H, 3.67; N, 13.13.Please cite this article in press as: Abdou, W.M. et al., Developing eﬃcient protoco
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5,6-dihydro-1H-pyrazolo[4,3-b]pyridine-6,6-diylbis-phosphonic
acid (12a) was obtained as white solid
Yield: 0.32 g (63.2%); mp > 300 C; tmax/cm1 1706 (C‚O),
1254, 1239 (2P‚O); dH (500 MHz, D2O) 1.17 (t,
3JHH = 7.6
Hz, 3H, H3CCH2O), 3.5 (s, 3H, H3CN), 4.14 (q,
3JHH = 7.6
Hz, 2H, H2CO), 7.41–7.64 (m, 5H, H-Ph); dC (125.7 MHz,
D2O) 177.6 (t,
2JPC = 24.9 Hz, C‚NMe), 162.3 (C‚O),
157.9, 148.1, 145.9, 128.9, 128.1, 123.2 (C-Ph, C-pyrazole),
118.5 (t, 2JPC = 28.1 Hz, CANH2), 113.1 (t,
3JPC = 8.9 Hz,
C‚CANH2), 60.6 (CH2O), 47.2 (t,
1JPC = 168.2 Hz, C-P2),
42.1 (CH3N), 14.9 (CH3CH2O); dP (202.4 MHz, D2O) 18.5,
19.2 (2d, 2JPP = 15.6 Hz, CP2); m/z (%) 469 [M
+2, 24%].
Anal. calcd. for C16H19N5O8P2 (471.30): C, 40.77; H, 4.06;
N, 14.86. Found: C, 40.86; H, 3.99; N, 14.92.
2.7.4. 7-Amino-3-(ethoxycarbonyl)-5-(ethylimino)-1-phenyl-
5,6-dihydro-1H-pyrazolo[4,3-b]pyridine-6,6-diylbisphosphonic
acid-salt (12b) was obtained as white substance
Yield: 0.33 g (65.3%); mp > 300 C; tmax/cm1 1710 (C‚O),
1256, 1234 (P‚O); dH (500 MHz, D2O) 1.18 (t,
3JHH = 7.8
Hz, 3H, H3CCH2N), 1.24 (t,
3JHH = 7.1 Hz, 3H, H3CCH2O),
4.13 (q, 3JHH = 7.8 Hz, 2H, H2CN), 4.16 (q,
3JHH = 7.1 Hz,
2H, H2CO), 7.46–7.74 (m, 5H, H-Ph); dC (125.7 MHz, D2O)
177.1 (t, 2JPC = 27.8 Hz, C‚NEt), 163.2 (C‚O), 157.9,
146.2, 143.8, 128.1, 128.9, 124.2 (C-pyrazole, C-Ph), 116.3 (t,
2JPC = 29.8 Hz, CANH2), 113.6 (t,
3JPC = 7.9 Hz,
C‚CANH2), 62.3 (CH2O), 56.1 (CH2N), 44.9 (t,
1JPC = 169.5 Hz, C-P2), 15.9 (CH3CH2O), 15.2 (CH3CH2N);
dP (202.4 MHz, D2O) 18.6, 19.3 (2d,
2JPP = 15.5 Hz, C-P2);
m/z (%) 483 [M+2, 28%]. Anal. calcd. for C16H19N5O8P2
(485.32): C, 42.07; H, 4.36; N, 14.43. Found: C, 42.16; H,
4.29; N, 14.34.
2.7.5. 2-(4-(Dimethylamino)phenyl)-2-(2-
mercaptophenylamino)ethane-1,1-diylbisphosphonic acid-salt
(17a) was obtained as yellow crystals
Yield: 0.34 g (68.3%); mp > 300 C; tmax/cm1 1251, 1229
(2P‚O); dH (500 MHz, D2O) 2.96 (s, 6H, NMe2), 3.87 (td,
3JHH = 10.2,
2JPH = 17.4 Hz, 1H, HC-P2), 4.45 (td,
3JHH = 10.2,
3JPH = 6.9 Hz, 1H, HC-Ar), 6.65–7.22 (m, 8H,
H-Ar); dC (125.7 MHz, D2O) 148.5, 147.2, 132.4, 129.9,
125.6, 123.5, 116.8, 114.7 (C-Ar), 139.6 (t, 3JPC = 8.2 Hz,
C-Ar), 65.1 (t, 2JPC = 27.1 Hz, CHANH), 45.4 (t,
1JPC = 184.4 Hz, C-P2), 40.9 (Me2C); dP (202.4 MHz, D2O)
19.7, 20.1 (2d, 2JPP = 21.9 Hz, C-P2); m/z (%) 430 [M
+2,
17%]. Anal. calcd. for C16H22N2O6P2S (432.37): C, 44.45; H,
5.13; N, 6.48; S, 7.42. Found: C, 44.52; H, 5.05; N, 6.39; S, 7.32.
2.7.6. 2-(4-Hydroxyphenyl)-2-(2-mercaptophenylamino)
ethane-1,1-diylbisphosphonic acid-salt (17b) was obtained as
yellow crystals
Yield: 0.3 g (62.4%); mp > 300 C; tmax/cm1 1253, 1232
(2P‚O); dH (500 MHz, D2O) 3.81 (td,
3JHH = 9.7,
2JPH = 18.4 Hz, 1H, HC-P2), 4.41 (td,
3JHH = 9.7,
3JPH = 6.7 Hz, 1H, HC-Ar), 6.62–7.27 (m, 8H, H-Ar); dC
(125.7 MHz, D2O) 156.9, 149.1, 131.3, 130.2, 124.9, 122.3,
120.4, 115.9 (C-Ar), 140.8 (t, 3JPC = 9.4 Hz, C-Ar), 64.6 (t,
2JPC = 28.3 Hz, CHANH), 44.9 (t,
1JPC = 186.8 Hz, C-P2);
dP (202.4 MHz, D2O) 18.9, 19.3 (2d,
2JPP = 23.4 Hz, C-P2);ls for synthesis, antiosteoarthritic, antiinﬂammatory assessments and docking
istry (2016), http://dx.doi.org/10.1016/j.arabjc.2016.02.019
Table 1 Antiarthritis evaluation results of N-BPs 4, 7, 11a,b,
16a,b & N-BP-acid-salts 5A, 8A, 12aA, 17aA,bA.
Antigen-induced arthritis
No. Dose sc
mg/kg
%
Inhibitiona
No. Dose scb
mg/kg
%
Inhibition
18 200 54*** 11b 200 23**
100 53*** 100 51**
50 44*** 60 35**
30 44***
4 200 38* 12aA 200 40**
100 28* 100 36***
50 – 60 52***
30 – 40 44*
5A 200 13** 16a 200 50***
100 38** 100 45***
60 42** 60 48***
40 40* 50 44***
7 200 53*** 16b 200 51***
100 46*** 100 46***
60 40*** 60 42**
40 38*** 50 40***
8A 200 56*** 17aA 200 58***
100 52*** 100 55***
50 40*** 60 48***
30 38*** 40 46***
11a 200 40** 17bA 200 60***
100 48** 100 56***
60 24* 60 44***
40 36***
a (***) p< 0.001, (**) p< 0.01, (*) p< 0.05.
b sc: subcutaneous.
6 W.M. Abdou et al.m/z (%) 403 [M+2, 27%]. Anal. calcd. for C14H17NO7P2S
(405.30): C, 41.49; H, 4.23; N, 3.46; S, 7.91. Found: C,
41.57; H, 4.14; N, 3.39; S, 8.01.
2.8. Biological procedures
2.8.1. Antigen-induced arthritis
According to the reported method by Nugent et al. (1993),
groups of 6 female albino mice, 6–8 weeks of age, were immu-
nized subcutaneously (sc) with an emulsion of methylated
bovine serum albumin (mBSA) and Freund’s complete adju-
vant supplemented with extra heat killed M-tuberculosis. Sec-
ondary immunizations were performed after 7 days, and after
a further 14 days the animals were challenged intraarticularly
with 200 mg of mBSA in saline into the left rear stifle joint.
The tested compounds 4, 5A, 7, 8A, 11a,b, 12aA, 16a,b, and
17aA,bA as well as the positive control, N-BP-drug (zole-
dronic acid, Zol) 18 were dissolved, suspended, or emulsified
in sterile saline and sonicated where appropriate to homoge-
neous doses. All compounds were then adjusted to pH 7.0
with 0.1 M NaOH and stored frozen in aliquots. Fresh ali-
quots were used for each day of dosing. Mice were dosed sc
in the scruff of the neck from the day of intraarticular mBSA
challenge (day 0) using a 5 of 7 day dosing regimen until the
conclusion of the study on day 28. The mBSA-injected stifle
joint was then skimmed, removed, and fixed in phosphate-
buffered formaldehyde solution prior to decalcification and
histological preparation. The assessment of arthritis was per-
formed on sagittal joint sections stained with hematoxylin and
eosin. Sections were graded 1 (mild) to 5 (severe) for soft tis-
sue inflammation, pannus formation, and extent to cartilage
and bone erosion. The changes (DPV) which occurred in the
arthritic control and treated rats (injected and noninjected-
mBSA) were quantitated on day 28 by mercury displacement
plethysmography. The component scores were summed to
give arthritis score. Statistical comparisons were performed
by one-way analysis of variance (ANOVA), compared with
vehicle-treated control. Resulted data are displayed in
Table 1.
2.8.2. Delayed-type hypersensitivity granuloma
According to the reported methods by Nugent et al. (1993) and
O¨sterman et al. (1997), groups of 6 female albino mice (25–
30 g) were sensitized with an emulsion of methylated bovine
serum albumin (mBSA) and Freund’s incomplete adjuvant
and dextran by sc injection over the inguinal lymph node.
Three weeks later, hydroxyapatite (HA) disks (6 mm diameter)
soaked in mBSA solution (30 mg/mL saline) were implanted sc
in dorsum of the mice (two disks, bilaterally). All tested com-
pounds (4, 5A, 7, 8A, 11a–d, 12aA, 12bA, 16a–d, 17aA, 17bA,
and Zometa) were prepared as solutions, suspensions, or
emulsion in sterile saline and sonicated where appropriate to
homogeneous doses, and the pH was adjusted to 7.4 with
0.1 M NaOH. Each mouse received compound in a volume
of 0.1 mL/10 g body weight sc in the scruff of the neck. Dosing
commenced on the day of implantation of the mBSA soaked
disks and was continued thereafter on a daily basis until day
nine, when the mice were euthanized. The granulomatous
lesions were then excised and both wet and dry tissue weights
measured. Results were analyzed by students paired test.
Resulted data are displayed in Table 2. Potency of the testedPlease cite this article in press as: Abdou, W.M. et al., Developing eﬃcient protoc
studies of nitrogen-containing bisphosphonate derivatives. Arabian Journal of Chemcompounds was calculated regarding zoledronic acid, reference
standard according to the following equation:
%Potency ¼ Group% edema inhibition of tested compound
Group% edema inhibition of zoledronic acid2.8.3. Toxicity evaluation of promised BP-derivatives 7, 16a, and
17bA
The LD50 determination of the most promising synthesized
and antiinflammatory active agents (7, 16a, and 17bA) was car-
ried out by the standard known LD50 method in mice (Ka¨rber,
1931). Albino mice weighing 20–25 g were divided into six
groups of six mice each. Administrations of the tested com-
pounds dissolved in the same vehicle solution in 500, 750,
and 1000 mg/kg (body weight) were given intraperitoneally.
Control groups were given in buffer solution only. Toxic
symptoms, mortality rates, and postmortem findings in each
group were recorded 24 h post administration.
LD50 of the tested compounds were calculated according to
the following formula:
LD50 ¼ Dm  Rðz dÞ=n
where Dm is the largest dose, which kills all animals, z is the
mean of dead animals between two successive doses, d= the
constant factor between two successive doses, n is the number
of animals in each group, R is the sum of (z  d).ols for synthesis, antiosteoarthritic, antiinﬂammatory assessments and docking
istry (2016), http://dx.doi.org/10.1016/j.arabjc.2016.02.019
Table 2 DTH-GRA results of synthesized N-BPs and N-BP-acid salts.a
No. Dose sc mg/kg % Inhibition of
granuloma
% Potency (wet) No. Dose sc mg/kg % Inhibition of
granuloma
% Potency (wet)
Dry wt Wet wt Dry wt Wet wt
18 100 47*** 44*** 100 16a 100 68*** 65*** 144.7
4 100 31* 33* 65.9 50 54*** 62***
5A 100 14* 18** 29.8 25 43*** 55***
7 100 64*** 66*** 136.2 16b 100 66*** 65*** 140.4
50 48*** 44*** 50 63*** 60***
25 38*** 35*** 25 50*** 52***
8A 100 20* 26* 42.6 16c 100 48*** 49*** 102.1
11a 100 44** 46** 93.6 50 38*** 45***
11b 100 41** 42** 87.2 16d 100 50** 48** 106.4
11c 100 40*** 38*** 85.1 50 52** 47**
11d 100 35*** 38*** 74.5
12aA 100 16* 20* 34.1 17aA 100 19* 22* 40.4
12bA 100 18* 24* 38.3 17bA 100 18* 25* 38.3
a (***) p< 0.001, (**) p< 0.01, (*) p< 0.05.
Scheme 2 Synthesis of N-BP 7, N-BP-acid 8 & its salt 8A.
N-Bisphosphonic acids vs arthritis & chronic inflammation 73. Chemistry and results of biological studies
3.1. Chemistry
We adopted two different protocols for synthesis of our tar-
gets, N-BPs: (i) consisted of coupling azido-substrates with
the phosphorus reagent, tetraethyl methylenebisphosphonate
(1)/catalyzed by sodium ethanolate (EtONa); (ii) involved
one-pot three-component synthesis, by applying 1 in an alka-
line solution to carbodiimide- or Schiff-base derivatives, ini-
tially generated in situ.
Schemes 1 and 2 describe synthesis of b-amino-BPs 4, 7 and
their acid analogs 5 and 8 from the coupling condensation of 1
with the azides 2 and 6. When the azide 2 (Pokhodylo et al.,
2010) was caused to react with slight excess of phosphonyl car-
banion 1 in EtONa solution, tetraethyl (3-amino-4,5,6,
7-tetrahydro-2H-[1]benzothieno-[2,3-b]pyrrole-2,2-diyl)bispho
sphonate (4) was isolated in 87.6% yield. As the pharma labo-
ratories proved remarkable therapeutic value of BP-acids than
BP-esters (Fleisch, 1995, 1988), hydrolysis of 4 to the corre-
sponding acid 5 was undertaken using trimethylsilyl bromide
(TMS-Br) in chloroform, followed by quenching with water.
The resulted acid 5 is hygroscopic and can be kept only underScheme 1 Synthesis of N-BP 4, N-BP-acid 5 & its salt 5A.
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solution of aqueous NaOH (10%/Methanol, 20 mL (1:3 v/v)
for 1 h, followed by concentration to give its disodium salt
5A (Nugent et al., 1993; Zhou et al., 2014) (Scheme 1).
The IR (tmax/cm
1) spectrum of N-BP 4 revealed the lack of
the azido- and the nitrile groups and revealed the presence of
stretching frequencies at 3441–3333 (NH2), P‚O (1254, free),
1234 (P‚O, H-bonded, due to its H-bonding with one proton
of the amino group), and at 1075, 1029 (PAOAC). In this con-
text, the NH2-protons were displayed in the
1H NMR (CDCl3,
dH) spectrum at 6.36 and 8.73 (2br, 2  1H) ppm. Further-
more, the 13C NMR (CDCl3, dC) spectrum of 4 revealed
among others, two triplets at 77.4 (t, 1JPC = 179.4 Hz, C-
P2), and 120.6 (t,
2JPC = 33.6 Hz, CANH2) and its
31P
NMR (CDCl3, dP) showed two doublets peaks at 21.5, 24.2
(2d, JPP = 24.2 Hz). For the N-BP-acid 5, the
31P NMR
(D2O, dP) chemical shifts were displayed at 18.8, 19.4 ppm
(2d, JPP = 16.3 Hz) (Du et al., 2002; Turhanen andls for synthesis, antiosteoarthritic, antiinﬂammatory assessments and docking
istry (2016), http://dx.doi.org/10.1016/j.arabjc.2016.02.019
8 W.M. Abdou et al.Vepsaelaeinen, 2008). As displayed in Scheme 1, the azides
smoothly react with the reagent 1 in refluxing ethanol with
the evolution of nitrogen to yield the intermediate 3 (Deep
et al., 1991; Cadogan et al., 1978). Further reduction of the
cyano group and intramolecular cyclization led to the product
4. The hydrolysis of the nitrile group was observed due to the
presence of the alkaline medium and the heating.
Similarly, the fused pyrrole-2,2-diylbisphosphonate 7 was
synthesized in 84.8% yield by treating ethyl 4-azido-5-cyano-
1-phenyl-1H-pyrazole-3-carboxylate (6) with the phosphorus
reagent 1 in EtONa solution at r.t. under the same reaction
conditions. It is notable to mention that the azide 6 was pre-
pared and identified for the first time. Compound 7 underwent
ester cleavage as previously mentioned to give 8, followed by
its conversion to its disodium salt 8A. The 1H-, 13P-, and 13C
NMR data of 7 and 8 are consistent with the assigned struc-
tures (see the experimental section) (Scheme 2).
Next, one-pot three-component reactions were applied for
the synthesis of N-BPs 11a–d and relevant N-BP-acids 12a,b
(Scheme 3). The first step of the process involved the
iminophosphorane (A) formation (90%) from the reaction of
the azide 6 with Ph3P in CH2Cl2. The precipitated phospho-
rane (A) was treated with a proper isocyanate 9a–d in tetrahy-
drofuran (THF) to give the required carbodiimides 10a–d in
>80% yields via the aza-Wittig reaction. N-
Heterocumulenes 10a–d were highly unstable, and should be
quickly freed from Ph3PO, and could be kept at 5 to 0 C
for few days (Liu et al., 2008; Abdou et al., 2013). Further
addition of ethanolate solution of phosphonyl carbanion 1 to
10a–d afforded the target fused pyridine-3,3-diyl-bisphospho
nates 11a–d in 62–74% yields. 11a,b underwent ester cleavage
as previously described to afford the respective acids 12a, 12b
followed by their disodium salts 12aA and 12bA (Scheme 3).
The IR absorptions (tmax/cm
1) for 11a–d showed bands
within the ranges 1259–1254 (P‚O, free) and 1234–1226
(P‚O, H-bonded). The NH2 protons in 11a–d were observed
at 6.31 and 8.72 ppm in their 1H NMR (CDCl3, dH). The
carbon chemical shifts for CP2, CNH2, and C‚NMe in 11a
(as a representative example) were observed in their expected
region at dC 47.8 (t,
1JPC = 168.7 Hz, CP2), 118.8 (t,
2JPC = 28.4 Hz, CANH2), and at 178.3 (t,
2JPC = 25.2 Hz,
C‚NMe). The 31P NMR (CDCl3, dP) chemical shifts of 11aScheme 3 Synthesis of N-BPs 11a–d, N
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ionization mass spectra of 11a–d gave molecular ions and diag-
nostic N-BP-daughter ion peaks at their expected m/z values.
For the N-BP-acids 12a,b, the 31P NMR (D2O, dP) chemical
shifts were displayed at d  18–19 ppm.
In another type of multi component reaction (MCR), the
Schiff-base intermediates 15 generated in situ from 2-
aminobenzenethiol (13) and the proper aldehyde 14a–d were
trapped by phosphoryl carbanion 1 in DMF solution contain-
ing lithium hydride (LiH) (Keglevich and Ba´lint, 2012; Li
et al., 2014). After the working up, N-BPs 16a–d were obtained
in 58–68% yields, via the addition reaction at the exocyclic imi-
nes. N-BPs 16a,b underwent ester cleavage using TMSBr, as
previously mentioned to afford the respective acids 17a, 17b
followed by conversion to their disodium salts 17aA and
17bA (Scheme 4).
In the IR (tmax, cm
1) spectra of 16a–d showed the NH
band the range 3433–3357 and the SH moiety at 2558 (free
thiol), the two P‚O bands within the range 1262–1254 (free)
and 1242–1228 (H-bonded). The 1H NMR (CDCl3, dH) spec-
trum of 16a, as a represented examples exhibited two types
of methine protons with different chemical shifts at 3.84 (td,
JHH = 9.8,
2JPH = 17.7 Hz, H
aC-P2) and at dH 4.45 ppm (td,
JHH = 9.8,
3JPH = 6.8 Hz) ascribed to the proton at the exo-
cyclic asymmetric carbon (HbAC*AAr). The 31P NMR
(CDCl3, dP) chemical shifts of 16a–d were observed at
dP  26, 24 (2d, JPP  24 Hz). The presence of the free thiol
moiety in the IR and 1H NMR spectra as well as the dH data
of the exocyclic methine-hydrogens confirms the assigned
structure and rule out any kind of SH-interaction in the reac-
tion to form a heterocycle.3.2. Pharmacology
Bisphosphonates (BPs) have been proven to be an important
asset in the treatment and prevention of bone resorption and
osteoporosis (Fleisch, 1995, 1988; Balakrishna et al., 2011).
However, they seem to have different effect on hypocalcemia
resulted from diseases such as tumor-induced osteolytic bone
diseases, chronic inflammation, and human arthritis
(Balakrishna et al., 2011).-BP-acids 12a,b & salts 12aA, 12bA.
ols for synthesis, antiosteoarthritic, antiinﬂammatory assessments and docking
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Figure 1 Structures of bisphosphonates and pyrophosphate.
Scheme 4 Synthesis of N-BPs 16a–d, N-BP-acids 17a,b & salts 17aA, 17bA.
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Elaborating a new entity in drug discovery needs optimization:
Data Base, permeability, and Computer Assisted Programs are
used for this purpose. PASS program is an important tool to
be used for designing in drug discovery. Prospective biological
activity spectra of the molecular structures of synthesized N-
BPs 4, 7, 11a–d, 16a–d, and N-BP-acids 5, 8, 12a,b, 17a,b,
starting materials 2 and 6 as well as the reference drug zol-18
were predicted in the early stage of the investigation. The
computer-assisted molecular modeling (CAMM) program:
PASS program 2012.1 version (IBMC, Moscow, Russia) was
adopted for designing – in silico – the potential structures
(Da Silva et al., 2010; Lagunin et al., 2003). Data of the PASS
results were presented as a list of activities (supplementary
materials, appendix 1). The study indicated that the main
expected biological activity of the designed compounds was
the antiosteoarthritic and antiinflammation potencies as com-
mon properties among these compounds. Furthermore, the
results demonstrated that structures 7, 8, 16a, 16b, 16d, and
17b are the most molecules of potential efficacy while com-
pounds 4, 11a, 11b, 12b, and 16c showed moderate activity.
On the other hand, BP-derivatives 2, 5, 6, 11c, 11d, 12a, and
17a displayed only weak potency.
3.2.2. Bioassays
The articular pathology of antigen-induced arthritis (AIA)
(Nugent et al., 1993; O¨sterman et al., 1997) involves an initial
intense inflammatory synovitis followed by chronic inflamma-
tion and severe erosion of articular cartilage and subchondral
bone resembling human rheumatoid arthritis (RA) (Nugent
et al., 1993; Brackertz et al., 1977). Both the synovitis and joint
destruction are unaffected by non-steroidal antiinflammatory
drugs (NSAID) (Nugent et al., 1993) but can be suppressed
by corticosteroids such as dexamethasone.
The delayed type hypersensitivity granuloma assay is a
model of chronic inflammation, in which mice were previously
sensitized to methylated bovine serum albumin (mBSA) and
surgically implanted with hydroxyapatite disks (two per
mouse) soaked in mBSA in order to generate granulomas.
This model is not affected by tradition NSAID such asPlease cite this article in press as: Abdou, W.M. et al., Developing eﬃcient protoco
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thritic properties of bisphosphonic acids (BPs) are poorly
understood and have not been demonstrated in any other
models of arthritis (Markusse et al., 1990). Furthermore, the
antiinflammatory potential of BP-acids has been largely
ignored (Daoud et al., 1987; Hyvonen and Kowolik, 1992).
Another article reported that may be BPs and BP-acids take
different pathways (Nugent et al., 1993).
3.2.3. Antiarthritis
The antiarthritic assay result was displayed in Table 1. Data
reflected the effects of sc administered selective six out of 10
new N-BPs, 4, 7, 11a,b, 16a,b and five out 6 new N-BP-acid
salts, 5A, 8A, 12aA, 17aA and 17bA on AIA in a mouse model
over 28 days. Zometa (18, zoledronic acid, Fig. 2), which is
N-BP-acid drug was used as a positive control since it revealed
an activity against RA (Dunn et al., 1990). In our experiments,
18 (dose: 30–200 mg/kg) exerted significant inhibitory effects
on the arthritis, and in general the tested compounds displayed
a moderate to good activity in the same dose range as 18.
These exceptions were 17aA, 17bA (N-BP-acid salts), which
showed higher inhibition (p< 0.001) at 40–200 mg/kg. Com-
pound 8 also displayed a significant inhibition (p< 0.001) at
30–200 at a slightly higher range (100–200 mg/kg). The N-
BPs 7, 16a, 16b, and 11a revealed an excellent inhibition
(p< 0.001) at 60–200 mg/kg whereas they showed only a mar-
ginal activity at a higher dose (100 mg/kg). Finally, compound
11b displayed a good activity at 100 mg/kg, while 4, 5A showed
only a marginal one at 100–200 mg/kg, which is not statisti-
cally remarkable.ls for synthesis, antiosteoarthritic, antiinﬂammatory assessments and docking
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The previous eleven compounds and others (all sixteen new
compounds) were profiled in a delayed-type hypersensitivity
granuloma model (Nugent et al., 1993). Thus, the tested com-
pounds 4, 5A, 7, 8A, 11a–d, 12aA,bA, 16a–d, and 17aA,bA as
well as the positive control Zometa 18 administered sc, and
the results were displayed in Table 2. Compound 18 repro-
ducibly inhibited granuloma wet and dry weights. Bisphospho-
nate esters 7, 16a and 16b significantly inhibited (higher than
the positive control) the granuloma in a dose-dependent man-
ner at the doses examined (25–100 mg/kg), while the esters 11a,
b and 16c,d exerted significant inhibition, which were almost
equivalent to that of 18 over the same dose, at 100 mg/kg.
Others 4, 11c,d displayed moderate activity against dry/wet
granuloma and were not dose related. In contrast, the acid
salts 5A, 8A, 12aA,bA and 17aA,bA, all showed dramatic drop
in the activity in relative to their phosphonate ester analogs
against the dry/wet weight granuloma.
The structure activity correlation based on the obtained
results in Tables 1 and 2 indicates that bisphosphonate esters
7, 16a, 16b showed an excellent efficacy in both models. How-
ever, the inhibition of DTH-GRA was not always predictive of
the activity of the BPs in the AIA models, suggesting that anti
arthritis/antiinflammatory activity may involve more than one
mechanism that the effect of BPs as anti-inflammatory is better
than the parallel BP-acids (Nugent et al., 1993). In favor of this
suggestion speaks the fact that while some BP-acid salts 8A,
17aA and 17bA demonstrated excellent antiarthritic properties,
these acids showed only moderate antiinflammatory potential.
The fact that S,N-BPs 16a–d induce significant antiinflamma-
tory property implies that the presence of a free thiol moiety
enhances the antiinflammatory efficacy of these compounds
(Abdou et al., 2006; Almstead et al., 1999; Cawston, 1996;
Siestema and Ebetino, 1994). Furthermore, this result proba-
bly (suggested by the referee) should be due to the different
lipophilicity, and permeability, of the esters with respect to
the acids. Probably the esters were hydrolyzed in vivo with dif-
ferent time, and in the arthritic test that was performed in
28 days with somministration after 5 or 7 days the difference
between the acids and the esters is reduced with respect to
the anti-inflammatory test, that was performed in 9 days with
a daily somministration. At this point, the comparison of the
activity of NBPS with NBP-acids is not completely correct.
Furthermore, the analysis of the biological activity spectra
prediction of the new compounds made in this publication is a
good example of in silico study of chemical compounds before
their experimental investigations. The analysis was performed
using the free available web site with the internet version of
PASS and PharmaExpert: http://www.ibmc.msk.ru/PASS
(CAMM) (Da Silva et al., 2010; Lagunin et al., 2003). The
spectrum for a substance is a list of the biological activity types
for which the probability to be revealed (Pa) and the probabil-
ity not to be revealed (Pi) are calculated. Pa and Pi values areN N P(OH)2
OH
(HO)2P O
O
Figure 2 Structure of zoledronic acid 18.
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material, appendix 1). By default, in PASS Pa= Pi value is
chosen as a threshold, therefore all compounds with Pa> Pi
are suggested to be active. Correlation between the results of
the computer-assisted prediction and the in vivo pharmacolog-
ical results is demonstrated in Table 3.
3.2.5. Toxicity of the promised products
Toxicological study of the most promising synthesized active
compounds 7, 16a and 17bA was performed using medium
lethal dose 50% (LD50) standard method (Ka¨rber, 1931) in
mice in 500, 750, and 1000 mg/kg (body weight), i.e. 5 folds
of the used antiarthritis and antiinflammatory effective doses.
However, no toxic symptoms or mortality rates were observed
after 24 h post administrations explaining the safe behavior of
the used doses.
3.2.6. Molecular modeling docking studies
Molecular docking of the new bisphosphonate esters (N-BPs)
4, 7, 11a–d, 16a–d, relevant N-BP-acids 5, 8, 12a,b, 17a,b,
and the reference drug zoledronic acid (Zol, 18) into the
human farnesyl pyrophosphate synthase (hFPPS, PDB code:
2F8C protein) (Rondeau et al., 2006) was performed using
the Accelrys Discovery Studio 2.5 modules (Girgis et al.,
2011; Shahin et al., 2014). The results are displayed in Table 4.
Considering N-BP-acids, except 5, BP-acids 8, 17a,b
showed markedly higher docking scores than the reference
drug 18 while 12a,b showed close docking scores to 18. On
the other hand, all N-BPs indicated lower scores than the same
reference. Description of the binding sites of interactions
between these most active molecules 8, 17a, 17b and the
enzyme in comparison with the reference drug 18 is recorded
in Fig. 3. The binding interaction forces of the lead compound
18 at the binding sites showed 6H-bonds with the amino acids
# Arg 112 (2 HB), Asp 103 (3 HB), and Asp 107 (1 HB), but
didn’t show p–p interactions; the Cdock score = 49.67 kcal/
mol. This assumes that the interaction of the reference 18 with
these three amino acids is essential for the activity and that
they represent the catalytic triad of such enzyme. Concerning
our tested molecules, compound 17b showed docking
score = 53.41 kcal/mol, and 8 HB with Arg 112 (2 HB),
Asp 103 (3 HB), Asp 107 (2 HB) and Gln 96 (1 HB). Com-
pound 17a showed docking score = 50.85 kcal/mol and 7
HB with Arg 112 (1 HB), Asp 103 (2 HB), Asp 107 (2 HB),
Asp 174 (1 HB) and Gln 96 (1 HB). In addition, compound
8 showed docking score (50.00 kcal/mol) with 3 HB at the
same triad [Asp 103 (2 HB), and Asp 107 (1 HB) and one p–
p interaction with Arg 112]. These data are predicting that
N-BP-acids have the same mode of action like the reference
drug 18, but with higher efficacy as inhibitor for FPPS enzyme
and slightly higher activity. While compound 12b showed
nearly similar docking score (49.81 kcal/mol) in comparison
with 18, with 5 HB at the same catalytic triad [Arg 112 (2 HB),
Asp 103 (2 HB), and Asp 107 (1 HB), and one p–p interaction
with Arg 60].
On the other hand, the prepared ester bisphosphonates 4, 6,
11a–d, 16a–d showed lower docking scores and fewer number
of H-bonding than the reference drug 18, as shown in Table 4.
The data also indicate that these compounds have less inhibi-
tory activity for FPPS enzyme. Fig. 3 presents the binding sites
of interactions between the most active molecules 8, 17a, 17bols for synthesis, antiosteoarthritic, antiinﬂammatory assessments and docking
istry (2016), http://dx.doi.org/10.1016/j.arabjc.2016.02.019
Table 3 Correlation between the results of the computer-assisted prediction and the in vivo pharmacological results.a
Comp. Predictionb
Pa*/Pa**
P/Ec
(Anti-arthritis)
P/E
(Anti-inflammation)
Comp. Prediction
Pa*/Pa**
P/E
(Anti-arthritis)
P/E
(Anti-inflammatn)
18 0.847 +/+ +/+ 12a 0.675 +/+ +/+
0.980 0.980
4 0.702 +/ +/+ 12b 0.742 NT +/+
0.612 0.672
5 0.675 +/ +/+ 16a 0.762 +/+ +/+
0.669 0.684
7 0.782 ++ +/+ 16b 0.741 +/+ /+
0.962 0.124
8 0.442 +/+ +/+ 16c 0.770 NT +/+
0.512 0.672
11a 0.570 +/+ +/+ 16d 0.607 NT +/+
0.764 0.776
11b 0.577 +/+ +/+ 17a 0.536 +/+ +/+
0.964 0.904
11c 0.706 NT +/+ 17b 0.589 +/+ +/
0.770 0.564
11d 0.526 NT +/+
0.967
a AAP, antiarthritis: 74.5%; AAP, antiinflammation: 99.5%.
b Pa*/Pa**: Propable activity (Pa) as antiarthritis/propable activity (Pa) as an antiinflammatoric agent.
c P/E: prediction result/evaluation of bioscreening result.
Table 4 Molecular modeling docking results.
No. Docking score (kcal/mol) HB & lipophilic interactions No. Docking score (kcal/mol) HB & lipophilic interactions
18 49.6774 2 HB (ARG 112) 12a 48.649 2 HB (ASP 103)
3 HB (Asp 103) 3 HB (ARG 112)
1 HB (ASP 107) 1 (+)-p–p-Interaction (ARG 60)
4 36.1248 1 HB (ASP 103) 12b 49.8194 2 HB (ASP 103)
1 HB (ASP 107)
2 HB (ARG 112)
1 (+)-p–p-Interaction (ARG60)
5 39.5462 2 HB (ARG 112) 16a 43.6762 2 HB (ARG 112)
2 HB (ASP 103) 1 (+)-p–p-Interaction (ARG112)
2 HB (ASP 107)
7 49.2206 1 HB (ARG 112) 16b 39.6825 1 HB (ASP 103)
2 (+)-p–p-Interaction (ARG 112) 1 HB (ARG 112)
8 50.0093 2 HB (ASP 103) 16c 39.1039 3 HB (ASP 103)
1 HB (ASP 107) 2 HB (ASP 107)
1 (+)-p–p-Interaction (ARG 112) 1 (+)-p–p-Interaction (ARG112)
11a 44.2512 1 HB (GLN 96) 16d 38.1832 2 HB (ARG 112)
1 (+)-p–p-Interaction (ARG 60) 1 HB (ASP 103)
11b 38.5265 2 HB (ARG 112) 17a 50.8548 1 HB (ASP 174)
2 HB (ASP 107)
2 HB (ASP 103)
1 HB (ARG 112)
1 HB (GLN 96)
11c 42.156 1 HB (ARG 112) 17b 53.4131 2 HB (ASP 107)
2 (+)-p–p-Interaction (ARG 112) 3 HB (ASP 103)
1 (+)-p–p-Interaction (ARG 60) 2 HB (ARG 112)
1 HB (GLN 96)
11d 43.3475 1 (+)-p–p-Interaction (ARG 60)
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Figure 3 Binding sites of interactions between the most active molecules 8, 17a, 17b and the enzyme in comparison with the reference
drug 18. (A1) The ionization state of Zometa (18) after running prepared ligand by adjusting ionization method by selecting the parameter
(Rule base and not the pH base). (A2) 3D diagram of 18 with the binding site after rotating to the opposite side-view. It showed one OH of
PO3H2 engaged with HB with (Asp103) and (Asp107), while the other OH is free. (A) Docking of 18 with FPPS enzyme (Cdock
score = 49.6774); (B) Docking of 8 with FPPS enzyme (Cdock score = 50.0093); (C) Docking of 17a with FPPS enzyme (Cdock
score = 50.8548); (D) Docking of 17b with FPPS enzyme (Cdock score = 53.4131).
12 W.M. Abdou et al.
Please cite this article in press as: Abdou, W.M. et al., Developing eﬃcient protocols for synthesis, antiosteoarthritic, antiinﬂammatory assessments and docking
studies of nitrogen-containing bisphosphonate derivatives. Arabian Journal of Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.2016.02.019
N-Bisphosphonic acids vs arthritis & chronic inflammation 13and the enzyme in comparison with the reference drug 18. In
addition, a list of binding sites of interactions between all
new molecules 4, 5, 7, 8, 11a–d, 12a,b, 16a–d, and 17a,b as well
as the enzyme in comparison with the reference drug 18 are
displayed as supplementary material (Appendix 2).
3.2.7. Correlation between molecular docking studies and
antiarithritic-DTH-GRA biological evaluation
Since the inhibition of FPPS enzyme is an important step in
the inhibition of osteoclastic activity, it is now widely used
as an approach for preventing the bone loss associated with
osteoporosis and antiarthritis activity.
In this study, we found that the acids 17a,b, 12a,b, and 8
that showed significant docking scores and high numbers of
binding-site interactions at the hFPPS enzyme have the highest
antiarithritic activity among all the tested compounds and the
reference drug 18. The bisphosphonate molecules (4, 7, 11a–d,
16a–d) that showed less docking scores and fewer number of
binding-site interactions with hFPPS, also showed lower anti-
arithritic activity (Tables 1 and 4). The above conclusion indi-
cated that the correlation between the virtual docking scores
and the biological activities are closely matching to each other.4. Conclusion
In summary, efficient and useful two synthetic protocols were applied
to construct under mild conditions, various b-aminomethylene-1,1-bi
sphosphonates (N-BPs) in good to excellent yields (58–88%). We
attempted in this research work to utilize the high bone specificity of
the third generation of N-BPs that contain primary amine group as
one of the side chain (Bijvoet et al., 1995) to elaborate new entities
for treating rheumatoid arthritis and chronic inflammation. Other ele-
ments such as chemical moieties of potential anticatabolic activities,
e.g., the pyrrol and/or pyridine nucleus as well as the biological activity
spectra prediction using CAMM programs were also considered. The
obtained results indicated that three new BPs have antiarthritic/antiin
flammation activities higher than the positive control (BP-drug) at the
same doses. These three BP-acids have either free thiol and/or free
amino side chain groups. These groups may facilitate the binding to
the metal atom in the active site of the matrix metalloproteinases
(MMPs) (Almstead et al., 1999; Balakrishna et al., 2011; Cawston,
1996; Cheng and Oldfield, 2004). Finally, from previous (Barbier
et al., 1986; Hannig et al., 2007; Nugent et al., 1993) and present stud-
ies, it is concluded that osteoclast activity plays an important role in
bone loss in rheumatoid arthritis (RA). This suggests that osteoclast-
targeted therapies may effectively prevent skeletal damage in patients
with RA. Furthermore, docking studies for new compounds were per-
formed in order to explore their possible binding mode at hFPPS, PDB
code: 2F8C.Acknowledgement
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